Indian NGO wants Gilead patents cancelled
15-04-2020
Gilead told to waive remdesivir patent rights
02-04-2020
Gilead expands special access to potential COVID-19 drug
31-03-2020
Sundry Photography / Shutterstock.com
Gilead Sciences has agreed to drop the lucrative “orphan drug” designation for an antiviral touted as a potential coronavirus treatment, after criticism from activists and politicians including Bernie Sanders.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Gilead, orphan drug, COVID-19, coronavirus, antiviral, remdesivir, FDA, Bernie Sanders, monopoly, pandemic
